Rhapsido in United Arab Emirates

Rhapsido - overview

Adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamines. It is an Oral BTK inhibitor (tablet, twice daily) approved by the US FDA in 2025 and may be accessible to patients in United Arab Emirates through a Named Patient Program or personal-import pathway.

Access in United Arab Emirates

The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.

How Reserve Meds coordinates access in United Arab Emirates

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and United Arab Emirates-specific eligibility.
3. Treating physician in United Arab Emirates issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Rhapsido from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in United Arab Emirates.

Typical timeline for United Arab Emirates

End-to-end, most requests are completed in 2-6 weeks. United Arab Emirates's tier 1 regulatory maturity typically supports fast processing times.

What patients and physicians in United Arab Emirates ask

• Is the pathway legal in United Arab Emirates? Yes - it operates under United Arab Emirates's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in United Arab Emirates able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Rhapsido in United Arab Emirates

Join the Rhapsido waitlist